A securities class action has been filed in the USDC — E.D.PA. against FMC Corporation (FMC) (“FMC” or the “Company”), on behalf of all persons or entities who purchased or otherwise acquired FMC common stock between November 16, 2023, and February 4, 2025, both dates inclusive (the “Class Period”).

GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide. Current best-selling GSK products include Trelegy Ellipta, an inhaler used to treat asthma, and Shingrix, a vaccine that protects against shingles. For many years, however, GSK’s most lucrative product was a popular treatment for heartburn and acid reflux: Zantac.

The Complaint alleges that, throughout the Class Period, the Defendants misled FMC investors by failing to disclose that:

(1) FMC’s strategic restructuring plan called “Project Focus” was not succeeding in its goal of significantly lowering FMC inventory in the distribution channel;

(2) FMC’s channel inventories were not rebalancing or normalizing, and in fact were getting worse;

(3) Project Focus was lagging in its goal of accelerating manufacturing cost reductions;

(4) FMC’s cost-plus pricing arrangements with key distributors would significantly lower FMC’s revenues and profits in the near-term;

(5) FMC’s risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and

(6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis, thereby harming investors.

As a result of FMC’s fourth quarter 2024 revenue report, FMC’s stock price dropped $18.12 per share, or 33.5 percent, to close at $35.92 per share on February 5, 2025.

If you purchased FMC common stock during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.